Recommendations of the Polish Gynecological Oncology Society for the diagnosis and treatment of ovarian cancer

Basta, Antoni; Bidziński, Mariusz; Bieńkiewicz, Andrzej; Blecharz, Paweł; Bodnar, Lubomir; Jach, Robert; Knapp, Paweł; Kojs, Zbigniew; Kotarski, Jan; Markowska, Janina; Misiek, Marcin; Sznurkowski, Jacek Jan; Wicherek, Lukasz; Sawicki, Włodzimierz; Timorek-Lemieszczuk, Agnieszka; Bahyrycz, Jan; Mądry, Radosław

doi:10.15557/cgo.2017.0001

Cited by 33 publications

(42 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Even the slightest chance to avoid such radical surgery should be considered by experts and applied if possible, as in the case of this patient. Specialists in gynecology and oncology concluded that the best method in this case would be unilateral salpingo-oophorectomy with staging procedures [6,17]. In addition, adjuvant chemotherapy should be used after surgery.…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Gender Dysphoria disrupting the course of treatment of a recurrent Juvenile Granulosa Cell Tumor in an adolescent female - a case report.

Kwiatkowska

Kułak

Wertel

2020

Preprint

View full text Add to dashboard Cite

Background: We present a case an adolescent female patient with Gender Dysphoria (GD) who was diagnosed with a recurrent ovarian neoplasm - Juvenile Granulosa Cell Tumor (JGCT).Case presentation: A 17-year-old female patient presented multiple endocrine pathologies and a recurrent JGCT. During the surgery qualification process, the patient admitted to identifying herself as a male. The patient described being uncomfortable with her body and with the expected roles of her assigned gender. Due to that, the patient requested a total hysterectomy with a bilateral salpingo-oophorectomy. As a minor, she required parent permission, which was not granted. The patient underwent several specialist consultations, after which she agreed for unilateral removal of tumor-changed pathologies and additional hormonal, psychological, and psychiatric diagnostics.Conclusion: To the best of our knowledge, this is the first detailed report of co-occurrence of GD spectrum disorders and JGCT in an adolescent female. This case contains many therapeutic and ethical problems regarding both physical and mental health. It should be noted that adolescents with the GD spectrum rarely develop persistent transsexuality. Modulations from developmental psychology, psychotherapy, family dynamics, hormonal treatment, and the removal of JGCT in the presented case may have potential therapeutic implications for GD.

show abstract

Section: Discussionmentioning

confidence: 97%

“…It should be noted that, in the case of recurrent JGCT, total abdominal hysterectomy and bilateral salpingo-oophorectomy is the recommended method [16,17]. However, in the case of such a young patient, gynecologists should also take care of her reproductive health [1,9].…”

Section: Discussionmentioning

confidence: 99%

Gender Dysphoria disrupting the course of treatment of a recurrent Juvenile Granulosa Cell Tumor in an adolescent female - a case report.

Kwiatkowska

Kułak

Wertel

2020

Preprint

View full text Add to dashboard Cite

show abstract

“…The treatment of ovarian cancer is a difficult process, which includes combined therapy . To implement the most appropriate treatment, it is necessary to establish grading (G1, G2 or G3) and the histological type of OC .…”

Section: Standard Treatmentmentioning

confidence: 99%

“…To implement the most appropriate treatment, it is necessary to establish grading (G1, G2 or G3) and the histological type of OC . Optimal debulking surgery is the strongest prognostic factor for the survival rate at all OC stages .…”

Section: Standard Treatmentmentioning

confidence: 99%

“…70% [3]. It has also been proved that the OC incidence is related to breast cancer (BRCA) gene mutations (up to 20% of all OC cases) [8] or type II Lynch syndrome, which is associated with mismatch repair (MMR) deficiency in colorectal cancer (CRC) [10]. necessary to project and implement new effective therapies, including immunotherapies [18].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immunotherapies based on PD-1/PD-L1 pathway inhibitors in ovarian cancer treatment

Pawłowska

Suszczyk

Okła

et al. 2019

Clinical and Experimental Immunology

View full text Add to dashboard Cite

Summary Immunotherapies based on anti‐programmed death 1/programmed death ligand 1 (PD‐1/PD‐L1) pathway inhibitors may turn out effective in ovarian cancer (OC) treatment. They can be used in combination with standard therapy and are especially promising in recurrent and platinum‐resistant OC. There is growing evidence that the mechanism of the PD‐1/PD‐L1 pathway can be specific for a particular histological cancer type. Interestingly, the data have shown that the PD‐1/PD‐L1 pathway blockade may be effective, especially in the endometrioid type of OC. It is important to identify the cause of anti‐tumor immune response suppression and exclude its other mechanisms in OC patients. It is also necessary to conduct subsequent studies to confirm in which OC cases the treatment is effective and how to select patients and combine drugs to improve patient survival.

show abstract

Advances in ovarian cancer therapy

Cortez

Tudrej

Kujawa

et al. 2017

Cancer Chemother Pharmacol

451

431

View full text Add to dashboard Cite

Epithelial ovarian cancer is typically diagnosed at an advanced stage. Current state-of-the-art surgery and chemotherapy result in the high incidence of complete remissions; however, the recurrence rate is also high. For most patients, the disease eventually becomes a continuum of symptom-free periods and recurrence episodes. Different targeted treatment approaches and biological drugs, currently under development, bring the promise of turning ovarian cancer into a manageable chronic disease. In this review, we discuss the current standard in the therapy for ovarian cancer, major recent studies on the new variants of conventional therapies, and new therapeutic approaches, recently approved and/or in clinical trials. The latter include anti-angiogenic therapies, polyADP-ribose polymerase (PARP) inhibitors, inhibitors of growth factor signaling, or folate receptor inhibitors, as well as several immunotherapeutic approaches. We also discuss cost-effectiveness of some novel therapies and the issue of better selection of patients for personalized treatment.

show abstract

Recommendations of the Polish Gynecological Oncology Society for the diagnosis and treatment of ovarian cancer

Abstract: Due to the significant risk for ovarian cancer in carriers of BRCA1 and BRCA2 mutation, bilateral salpingo-oophorectomy is recommended after the patient has completed

Cited by 33 publications

References 88 publications

Gender Dysphoria disrupting the course of treatment of a recurrent Juvenile Granulosa Cell Tumor in an adolescent female - a case report.

Gender Dysphoria disrupting the course of treatment of a recurrent Juvenile Granulosa Cell Tumor in an adolescent female - a case report.

Immunotherapies based on PD-1/PD-L1 pathway inhibitors in ovarian cancer treatment

Advances in ovarian cancer therapy

Contact Info

Product

Resources

About